Norfolk coastal erosion victims offered mental health care
According to a Norfolk County Council report, which was published last year, Norfolk has part of the fastest eroding coastline in North West Europe.It is estimated that without action, the north Norfolk coastline could lose about 1,030 residential and commercial properties by 2105.The government said climate change increases the risk of coastal erosion.
Ruth Taylor, the social development manager at Norfolk and Waveney Mind, said: "We are aware that people in these communities feel very strong emotions about the subject of coastal change and the impacts of policy decisions around sea defences."These feelings are complex and interconnected, and they include anxiety, significant levels of anger, despair and depression, and overwhelming grief related to the threat of (or actual) loss of home, income, community networks and cultural assets."Other emotions include feelings of apathy and also powerlessness. Some individuals most directly affected may be experiencing post-traumatic stress disorder [PTSD] and what can be called 'Pre-TSD' in anticipation of the changes that are coming."Over the coming months, the Sustain Coastal project aims to work with communities to create a bespoke range of support activities and therapies.These are likely to include monthly walk and talk groups, drop-in wellbeing sessions and one-to-one support meetings for those most at risk of losing their property."In this bespoke project we will include a greater focus on managing trauma, adapting to change, grief tending activities and strengthening community connections," Ms Taylor added.
Norfolk and Waveney Mind said it had already run successful pilot activities in Sheringham and Happisburgh.The new project is funded by the Environment Agency, Department for Environment, Food and Rural Affairs (Defra) and the Coastwise Coastal Transition Fund in partnership with North Norfolk District Council.It is also supported by the Climate Psychology Alliance.A launch event, which is open to all affected residents, is will be held at St Mary's church rooms in Happisburgh from 18:00 GMT on Wednesday. A similar event will be held at the Pilgrim Shelter in Trimingham from 17:30 on 17 February.
Follow Norfolk news on BBC Sounds, Facebook, Instagram and X.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
17 hours ago
- Daily Mail
SMALL CAP IDEA: Ketamine drip therapy firm is taking on alcoholism
As the dust settles on its successful takeover of Awakn Life Sciences, investors are starting to appreciate the potential of Solvonis Therapeutics. Yet the current valuation of £23million doesn't tell the full story. Or perhaps it tells its own tale: that the Brits are blinkered, even oblivious to a story unfolding on the other side of the Atlantic that has real and positive implications for Solvonis. More on this later. First, it's probably worth refreshing ourselves as to what the company is and does. Quite simply, it is a biotech company that is developing potential treatments for illnesses such as alcohol abuse, post-traumatic stress disorder, and depression, where innovation and treatment options are sorely lacking. And they have been for a number of decades. It has four programmes, one in phase III, which on a more progressive and capital-deep market such as Nasdaq would in and of itself justify at least one additional nought to Solvonis' market capitalisation. Again, more on this later. Its lead drug is SNV-001, an experimental treatment being tested in advanced clinical trials for people with severe alcohol use disorder (AUD). It combines two approaches: a carefully controlled dose of ketamine (a dual anaesthetic and painkiller medicine that affects certain brain receptors) given by drip, and a course of cognitive behavioural therapy, or CBT, designed to specifically help prevent relapse. The aim is to see if using these together can help people stay off alcohol more effectively than either treatment alone. Early trial results for SNV-001 have been encouraging. In phase II testing, people given the treatment had 50 per cent fewer heavy drinking days compared to those who received a placebo. Even more striking, on average 86 per cent of participants stayed off alcohol for six months after treatment, while only 2 per cent had managed this before joining the trial. The results were so good that the UK Department of Health through the National Institute of Health and Care Research are co-funding the trial. Looking ahead, the company plans to seek what is called a mixed-full approval in both the UK and EU, which could mean up to 10 years of market exclusivity if successful. Its second asset is where the hidden value resides and where, I would contend, the UK investing public just isn't recognising the upside. Called SVN-002, it is an experimental treatment being developed in the much larger US alcohol addiction treatment market It uses esketamine, closely related to ketamine, and, crucially, a compound already being used in Johnson & Johnson's new blockbuster, Spravato, in nasal form, to combat treatment-resistant depression. Top marks if you made the link. Don't worry if you didn't; but pay attention at the back! So alike are the two compounds that Solvonis last month kicked off a process designed to provide scientific 'bridging' data linking SVN‑002 to Spravato. By referencing the existing drug, Solvonis aims to pursue the 505(b)(2) regulatory pathway, a route that allows companies to rely on existing data to streamline approval processes. Not only this, the company also hopes SVN-002 will be eligible under the same reimbursement codes as Spravato, potentially saving significant time and cost. Now, here's the eyes-on-stalk moment. Spravato is already generating annual revenues of more than $1billion and analysts believe this figure could actually peak at $5billion. However, its addressable market is a couple of million Americans with severe depression. Contrast this with the estimated 22 million people in the States who struggle badly with alcohol. As they say in the States, you do the math(s). American investors have not been slow to cotton on. Companies listed across there paddling in similar, or adjacent, pools, the likes of Atai Life Sciences, MindMed, GH Research and Compass Pathways, have been in lift-off mode. Meanwhile, pharma giant Abbvie is reported in the US business press last week to be preparing a $1billion offer for a privately owned-US peer of Solvonis, a company called Gilgamesh Pharmaceuticals. In other words, real buzz around the sector in the States that has so far been absent here in the UK, which is also reflected in valuations stateside, which are orders of magnitude larger than Solvonis. Atai, for example, has programmes barely emerged from phase I and carries a market capitalisation of more than $800million. That reflects America's greater understanding of not just biotech, but the potential of this new emerging area of treatment. Value inflexion points for companies such as Solvonis tend to come at the end of clinical studies – phase II usually, but also phase III. This is when large pharma is sufficiently emboldened to invest in the expensive process of follow-on studies, and/or pouring tens of millions of dollars into gaining regulatory sign-off. A licensing agreement of this type not only provides third-party validation of the work to date, it comes with financial kickers such as upfront and milestone payments. We already know that Solvonis has drafted in Pharma Ventures, a specialist in partnership and alliances of the sort outlined above, to shop SNV-001. So, one can safely assume conversations are taking place. It will be interesting to track the role in negotiations played by Solvonis chair Dennis Purcell. He is also a director of IGI, which recently cut a $1.9 billion deal with AbbVie, with $700million of that upfront. Okay, this was in the oncology arena, but Purcell has first-hand experience of going toe-to-toe with big pharma. And this will be crucial when talks hit the nitty-gritty phase. A recent research note penned by the team at Singers used the net present value of Solvonis' two clinical stage assets, allied to what it calls a 'risk-adjusted patient-based forecast', to come up with a 1.6p price target. So, what does all this mean? Well, it suggests Solvonis' share price of 0.37p may not reflect the company's true potential.
Medical News Today
3 days ago
- Medical News Today
What to know about chronic vs. acute post-traumatic stress disorder (PTSD)
When people talk about acute PTSD, they are likely referring to acute stress disorder, which is also called post-traumatic stress syndrome (PTSS). Acute stress disorder symptoms occur within the first month after someone experiences a traumatic contrast, when someone talks about chronic PTSD, they are likely referring to the standard definition of PTSD. In the standard definition of PTSD, symptoms occur for longer than 1 month after someone experiences a traumatic symptom criteria for acute stress disorder and PTSD are the same. The only difference is that a doctor may diagnose someone with PTSD if their symptoms last for more than 1 people with acute stress disorder are likely to develop PTSD, but not everyone with acute stress disorder will develop of acute stress disorder and PTSD may include:Re-experiencing symptoms: Examples include flashbacks and recurring nightmares or memories related to the traumatic event. Arousal and reactivity symptoms: Examples include feeling tense or easily startled, difficulty sleeping, and irritability. Cognition and mood symptoms: Examples include difficulty remembering key details about the traumatic event, difficulty concentrating, and no longer having an interest in previous hobbies. Avoidance symptoms: Examples include avoiding thoughts and feelings related to the traumatic event and staying away from reminders of it. People should note that examples in the list above are not exhaustive, and each individual may experience different symptoms of acute stress disorder and who suspects they are experiencing acute stress disorder or PTSD should contact a healthcare professional. A mental health professional can make an accurate diagnosis and recommend appropriate treatment, such as psychotherapy and more about PTSD17 symptoms of PTSD explainedRelationships and PTSD: What to knowTypes of PTSDIs PTSD hereditary? How genes play a role
Medical News Today
3 days ago
- Medical News Today
What to know about post-traumatic stress disorder (PTSD) and migraine
Research indicates there is a link between PTSD and migraine. However, research is limited, and scientists are still learning about the relationship between the conditions. The use of binary terms such as 'male' and 'female' or 'men' and 'women' in this article reflects the language of the sources we've used. Unless otherwise noted, it's unclear whether the research we reference included participants with expansive gender do not know whether migraine contributes to the development of PTSD or PTSD contributes to the development of migraine. A 2016 review of research found that PTSD symptoms were associated with a higher likelihood of experiencing frequent headaches or migraine episodes. The review authors also noted that individuals with PTSD who are experiencing intrusive reminders of a traumatic event may be most affected by migraine episodes or headaches.A 2017 study involving pregnant women found that the likelihood of experiencing PTSD is increased in individuals with migraine. The study authors suggested that PTSD screening could be beneficial for pregnant women with migraine.A 2011 review noted that one of the possible mechanisms linking migraine and PTSD could be a dysfunction between the hypothalamic-pituitary-adrenal axis and the autonomic nervous system. The hypothalamic-pituitary-adrenal axis regulates the autonomic nervous system and manages the stress response. The autonomic nervous system consists of the sympathetic and parasympathetic nervous systems. The sympathetic nervous system activates when the body is exposed to stressful stimuli, resulting in the fight, flight, or freeze the review authors highlighted that further research into the relationship between PTSD and migraine is who suspects they are experiencing PTSD or migraine should contact a healthcare professional. A doctor can make an accurate diagnosis and recommend appropriate treatment, if necessary. Learn more about PTSD17 symptoms of PTSD explainedTypes of PTSDRelationships and PTSD: What to knowPTSS vs. PTSD: What are the differences?
